EGFR and lung cancer: It has been recently shown that both wild-type and catalytically inactive mutants of JMJD5 cooperate with E3 ligase HUWE1 to destabilize EGFR and EGFR tyrosine kinase inhibitor-resistant mutants for proteasomal degradation in lung cancer cells [110].